Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for its small molecule drug candidate, TY-2699a. This oral, selective CDK7 inhibitor is under development for the treatment of various cancers, including breast, ovarian, prostate, pancreatic, and small cell lung cancers, as well as hematomas and other advanced tumors.
Preclinical Efficacy and Safety of TY-2699a
TY-2699a has demonstrated good inhibitory effects on multiple tumor models in preclinical in vitro and in vivo efficacy trials. The drug has also shown good tolerance and safety, providing a solid foundation for future clinical research and exploration. These positive preclinical results suggest that TY-2699a has the potential to be an effective treatment option for patients with these types of cancers.
Potential Response to Drug Resistance in Breast Cancer Models
Furthermore, TY-2699a has shown good activity in breast cancer models with acquired drug resistance to CDK4/6 inhibitors. This indicates that TY-2699a could be a potential choice for addressing drug resistance following targeted treatment with CDK4/6 inhibitors, offering a new therapeutic strategy for patients who have developed resistance to existing therapies.-Fineline Info & Tech
